STOCK TITAN

Standard BioTools Inc - LAB STOCK NEWS

Welcome to our dedicated news page for Standard BioTools (Ticker: LAB), a resource for investors and traders seeking the latest updates and insights on Standard BioTools.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Standard BioTools's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Standard BioTools's position in the market.

Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) introduces new automation solutions to enhance the Imaging Mass Cytometry workflow on the Hyperion XTi Imaging System, revolutionizing spatial biology in clinical and translational research. The advancements aim to increase sample throughput, provide rapid and detailed spatial analysis, and offer high-throughput tissue imaging capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
-
Rhea-AI Summary
Standard BioTools Inc. (LAB) partners with Bristol Myers Squibb to utilize the SomaScan Platform for clinical trials in multiple therapeutic areas. The platform offers a comprehensive analysis of proteomic biomarkers, aiding in drug response assessment and patient population identification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
Rhea-AI Summary
Standard BioTools Inc. (LAB) announces the exchange of Series B Preferred Stock for common stock with Viking Global Investors and Casdin Capital, aiming to streamline capital structure and attract new investors. The exchange resulted in the issuance of approximately 93 million shares of common stock at $2.75 per share, reducing dilution to less than 5%. The Company now has around 382.5 million shares outstanding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
Rhea-AI Summary
Standard BioTools Inc. achieved its FY2023 core financial objectives by reducing expenses and cash burn while increasing revenue and gross margins. The merger with SomaLogic strengthened the company's position in life sciences, resulting in combined pro forma revenue of $192 million and a balance sheet with $565 million in combined pro forma cash, cash equivalents, restricted cash, and short-term investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
-
Rhea-AI Summary
Standard BioTools Inc. (LAB) and Next Gen Diagnostics have signed a long-term agreement to enhance the automation of pathogen whole genome sequencing. The NGD-100, a version of Standard BioTools' Biomark X9 System, will be customized for NGD to streamline sample preparation. This collaboration aims to reduce the cost of bacterial sequencing to under $10/sample, addressing the key barriers in pathogen WGS. Standard BioTools' microfluidics technology, known for its scalability and automation, combined with NGD's advanced bioinformatics, will offer integrated pathogen sequencing services with rapid turnaround times and cost-efficiency. NGD has validated the accuracy of sequence-based diagnostics for antibiotic resistance prediction and infection transmission detection. The partnership signifies a significant advancement in Standard BioTools' growth strategy, expanding its microfluidic platform's impact in life sciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
partnership
-
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) announces participation in upcoming investor conferences to showcase breakthroughs in human health. President and CEO, Michael Egholm, PhD, to present at TD Cowen's 44th Annual Healthcare Conference and KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
conferences
Rhea-AI Summary
Standard BioTools Inc. (LAB) will report Q4 and full year 2023 financial results on February 28, 2024. The company aims to accelerate breakthroughs in human health. A conference call and webcast will discuss the results and operational progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
-
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) has announced a collaboration agreement with Navignostics AG to develop clinical research applications and service offerings using the Hyperion XTi™ Imaging System. This collaboration aims to expand access to high-quality data in clinical research, particularly in the fight against cancer, emphasizing the need for precision medicine strategies and robust technologies that offer critical biological insights to guide treatment decisions. Navignostics, founded in 2022, is dedicated to revolutionizing personalized diagnostics for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq: LAB) expects fourth quarter 2023 revenue of approximately $28 million and full year 2023 revenue of approximately $106 million, representing over 10% growth in core revenue and over 40% growth in instrument revenue compared to 2022. The company completed its merger with SomaLogic, Inc., expecting pro forma full year 2023 revenue of approximately $192 million and over $550 million in cash, cash equivalents, and short-term investments as of December 31, 2023. The CEO, Michael Egholm, expressed excitement about the combined company's progress and commitment to building a scalable, profitable suite of differentiated life science tools to accelerate breakthroughs in healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.37%
Tags
none
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq: LAB) completes merger with SomaLogic, creating a leading provider of differentiated multi-omics tools for research. The combined company has a formidable capital structure comprising over $500 million in cash and cash equivalents, aiming to self-fund future growth initiatives. The company is targeting large, high growth markets with a diverse portfolio of life sciences tools and is expected to realize $80 million in annual cost synergies by 2026. Key leadership team appointments have also been made.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
Standard BioTools Inc

Nasdaq:LAB

LAB Rankings

LAB Stock Data

1.11B
50.38M
0.64%
56.02%
3.19%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
US
South San Francisco

About LAB

fluidigm (nasdaq:fldm) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets. fluidigm’s systems consist of instruments, software, integrated fluidic circuits (ifcs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. the company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality. based in south san francisco, fluidigm offers an exciting and collegial working environment with excellent compensation and benefits, including equity.